Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

Hot Topics in PAH: What We’ve Learned in the Past Year

Access Activity

Overview / Abstract:

How can clinicians improve early detection of PAH? What are some practical strategies for managing PAH patients in today’s world? What recent data support current treatment strategies, and what are emerging therapeutic options? This 30-minute multimedia Q&A touchpoint “Hot Topics” CME activity features leading pulmonology expert Dan Schuller, MD, from Texas Tech University Health Sciences Center who discusses the latest data and recommendations, along with his insights for applying this information in clinical practice. This activity features engaging images, charts, and short video snippets. Dive into recommendations from the 6th World Symposium on Pulmonary Hypertension, new risk assessment tools, and more!

Expiration

Nov 29, 2022

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME, Respiratory Therapy CE

Format

Manuscript Review, Online

Credits / Hours

0.5

Accreditation

ACCME

Presenters / Authors / Faculty

Dan Schuller, MD
Professor and Chair
Department of Internal Medicine – Transmountain
Texas Tech University Health Sciences Center
Paul L. Foster School of Medicine
El Paso, TX

Activity Specialities / Related Topics

Cardiology / Cardiovascular, Emergency Medicine, Family Medicine, Internal Medicine, Primary Care, Pulmonary Medicine / COPD

Sponsors / Supporters / Grant Providers

Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

Keywords / Search Terms

ACHL PAH, Pulmonary Arterial Hypertension (PAH), Dr. Dan Schuller, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, Actelion, 6th World Symposium on Pulmonary Hypertension, TRITON,PDE5 inhibitor, prostacyclin, riociguat, endothelin receptor antagonist, ERA, combination therapy, COVID-19, telemedicine, CTD-PAH, COMPERA, REVEAL 2.0, REVEAL Lite 2, REPLACE trial, GRIPHON trial, IV selexipag, treprostini Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map